bimagrumab and tirzepatide Fat, not muscle: drugmakers in race for next weight-loss breakthrough Tirzepatide | Smarter Health Medical

Through my unique FLOA Protocol, we tackle insulin resistance, inflammation, and metabolic dysfunction to set you up for lifelong success

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

If patients can achieve these outcomes earlier, the future treatment pathway could change dramatically

GLP-1 Boosting Gut Support Unflavored 9oz